Group 1 - The company proposes to spin off its subsidiary, Mandi Co., and list it independently on the Hong Kong Stock Exchange [1] - The proposed spin-off will involve a distribution of all shares of Mandi to shareholders based on their ownership percentage and a global offering of new Mandi shares [1] - The Hong Kong Stock Exchange has confirmed that the company can proceed with the proposed spin-off [1] Group 2 - Upon completion of the spin-off, the company will no longer retain any interests in Mandi, and Mandi will cease to be a subsidiary of the company [1] - Mandi submitted an application to the Hong Kong Stock Exchange on November 20, 2025, for the approval of its shares to be listed and traded on the main board [1] - The listing document for Mandi is expected to be published on the Hong Kong Stock Exchange's website for review and download [1]
三生制药(01530.HK)拟分拆蔓迪国际并于港交所主板独立上市